Advocacy at a Glance 12/5/16 Advocacy at a Glance 12/5/16 Advocacy at a Glance Read More Analysis and Commentary 11/21/16 Analysis and Commentary 11/21/16 Significant Change Is Always Hard Read More Advocacy at a Glance 11/21/16 Advocacy at a Glance 11/21/16 Advocacy at a Glance Read More Analysis and Commentary 11/11/16 Analysis and Commentary 11/11/16 Ensuring and Advocating for an FDA that Works Read More Advocacy at a Glance 11/11/16 Advocacy at a Glance 11/11/16 Advocacy at a Glance Read More Analysis and Commentary 11/7/16 Analysis and Commentary 11/7/16 Alliance Has No Prognosis for the Lame Duck Read More Advocacy at a Glance 11/7/16 Advocacy at a Glance 11/7/16 Advocacy at a Glance Read More Analysis and Commentary 10/28/16 Analysis and Commentary 10/28/16 Musical Chairs and Post-Election Congressional Committee Leadership Read More Advocacy at a Glance 10/28/16 Advocacy at a Glance 10/28/16 Advocacy at a Glance Read More Analysis and Commentary 10/21/16 Analysis and Commentary 10/21/16 Plus ça Change, Plus c'est la Même Chose (or Maybe Not) Read More Advocacy at a Glance 10/21/16 Advocacy at a Glance 10/21/16 Advocacy at a Glance Read More Analysis and Commentary 10/14/16 Analysis and Commentary 10/14/16 And Now Much Depends on Election Day Outcomes Read More Advocacy at a Glance 10/14/16 Advocacy at a Glance 10/14/16 Advocacy at a Glance Read More Advocacy at a Glance 10/1/16 Advocacy at a Glance 10/1/16 A CR Gets Passed ... But Has Fiscal Implications Read More Advocacy at a Glance 10/1/16 Advocacy at a Glance 10/1/16 Advocacy at a Glance Read More Analysis and Commentary 9/23/16 Analysis and Commentary 9/23/16 FDA Purchasing Power is on the Line Read More Advocacy at a Glance 9/23/16 Advocacy at a Glance 9/23/16 Advocacy at a Glance Read More Analysis and Commentary 9/16/16 Analysis and Commentary 9/16/16 What to Expect When You are Expecting a Lame Duck Read More Advocacy at a Glance 9/16/16 Advocacy at a Glance 9/16/16 Advocacy at a Glance Read More Analysis and Commentary 9/9/16 Analysis and Commentary 9/9/16 Omnibus, Minibus, or Any Type of Bus at All? Read More Newer Posts Older Posts
Analysis and Commentary 11/21/16 Analysis and Commentary 11/21/16 Significant Change Is Always Hard Read More
Analysis and Commentary 11/11/16 Analysis and Commentary 11/11/16 Ensuring and Advocating for an FDA that Works Read More
Analysis and Commentary 11/7/16 Analysis and Commentary 11/7/16 Alliance Has No Prognosis for the Lame Duck Read More
Analysis and Commentary 10/28/16 Analysis and Commentary 10/28/16 Musical Chairs and Post-Election Congressional Committee Leadership Read More
Analysis and Commentary 10/21/16 Analysis and Commentary 10/21/16 Plus ça Change, Plus c'est la Même Chose (or Maybe Not) Read More
Analysis and Commentary 10/14/16 Analysis and Commentary 10/14/16 And Now Much Depends on Election Day Outcomes Read More
Advocacy at a Glance 10/1/16 Advocacy at a Glance 10/1/16 A CR Gets Passed ... But Has Fiscal Implications Read More
Analysis and Commentary 9/23/16 Analysis and Commentary 9/23/16 FDA Purchasing Power is on the Line Read More
Analysis and Commentary 9/16/16 Analysis and Commentary 9/16/16 What to Expect When You are Expecting a Lame Duck Read More
Analysis and Commentary 9/9/16 Analysis and Commentary 9/9/16 Omnibus, Minibus, or Any Type of Bus at All? Read More
